Cargando…

High MICB expression as a biomarker for good prognosis of colorectal cancer

INTRODUCTION: Major histocompatibility complex (MHC) plays an important role in colorectal cancer (CRC) immunity. However, the function of MHC class I chain-related B (MICB) molecule is not very clear. In this study, we explored the prognostic effect of MICB in colorectal cancer. MATERIAL AND METHOD...

Descripción completa

Detalles Bibliográficos
Autores principales: Feng, Qingyang, Yu, Shanchao, Mao, Yihao, Ji, Meiling, Wei, Ye, He, Guodong, Chang, Wenju, Zhu, Dexiang, Ren, Li, Xu, Jianmin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7230058/
https://www.ncbi.nlm.nih.gov/pubmed/32306128
http://dx.doi.org/10.1007/s00432-020-03159-0
_version_ 1783534872132845568
author Feng, Qingyang
Yu, Shanchao
Mao, Yihao
Ji, Meiling
Wei, Ye
He, Guodong
Chang, Wenju
Zhu, Dexiang
Ren, Li
Xu, Jianmin
author_facet Feng, Qingyang
Yu, Shanchao
Mao, Yihao
Ji, Meiling
Wei, Ye
He, Guodong
Chang, Wenju
Zhu, Dexiang
Ren, Li
Xu, Jianmin
author_sort Feng, Qingyang
collection PubMed
description INTRODUCTION: Major histocompatibility complex (MHC) plays an important role in colorectal cancer (CRC) immunity. However, the function of MHC class I chain-related B (MICB) molecule is not very clear. In this study, we explored the prognostic effect of MICB in colorectal cancer. MATERIAL AND METHODS: From 2008-05 to 2012-11, consecutive CRC patients of Zhongshan Hospital, Fudan University were retrospectively enrolled as primary cohort. The inclusion criteria were as follows: receiving primary radical resection, pathologically confirmed colorectal adenocarcinoma, no treatment before surgery, clinicopathological data available. Another cohort of CRC patients were collected from a public dataset GSE39582 of GEO database from 1987 to 2007 in the same criteria for validation. MICB was detected using immunochemistry and evaluated as prognostic biomarker. The cut-off value of MICB expression was calculated using X-tile software. RESULTS: Finally, 863 patients were enrolled in the primary cohort, and 556 patients were enrolled in the validation cohort. MICB expression was significantly associated with tumor size and primary histological type in primary cohort, and with primary tumor location and distant metastases in validation cohort. The survival analysis showed that patients with high MICB expression had significantly better overall survival in both primary (P = 0.002) and validation (P = 0.001) cohorts. The multivariate analysis also confirmed that high MICB expression was a significantly independent protective factor for overall survival in both primary (hazard ratio HR = 0.741, 95% CI 0.594–0.924) and validation (HR = 0.699, 95% CI 0.508–0.961) cohorts. CONCLUSION: For stage I–IV CRC patients, MICB was confirmed a novel independent prognostic factor. It could help better stratification of CRC prognosis. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1007/s00432-020-03159-0) contains supplementary material, which is available to authorized users.
format Online
Article
Text
id pubmed-7230058
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Springer Berlin Heidelberg
record_format MEDLINE/PubMed
spelling pubmed-72300582020-05-18 High MICB expression as a biomarker for good prognosis of colorectal cancer Feng, Qingyang Yu, Shanchao Mao, Yihao Ji, Meiling Wei, Ye He, Guodong Chang, Wenju Zhu, Dexiang Ren, Li Xu, Jianmin J Cancer Res Clin Oncol Original Article – Cancer Research INTRODUCTION: Major histocompatibility complex (MHC) plays an important role in colorectal cancer (CRC) immunity. However, the function of MHC class I chain-related B (MICB) molecule is not very clear. In this study, we explored the prognostic effect of MICB in colorectal cancer. MATERIAL AND METHODS: From 2008-05 to 2012-11, consecutive CRC patients of Zhongshan Hospital, Fudan University were retrospectively enrolled as primary cohort. The inclusion criteria were as follows: receiving primary radical resection, pathologically confirmed colorectal adenocarcinoma, no treatment before surgery, clinicopathological data available. Another cohort of CRC patients were collected from a public dataset GSE39582 of GEO database from 1987 to 2007 in the same criteria for validation. MICB was detected using immunochemistry and evaluated as prognostic biomarker. The cut-off value of MICB expression was calculated using X-tile software. RESULTS: Finally, 863 patients were enrolled in the primary cohort, and 556 patients were enrolled in the validation cohort. MICB expression was significantly associated with tumor size and primary histological type in primary cohort, and with primary tumor location and distant metastases in validation cohort. The survival analysis showed that patients with high MICB expression had significantly better overall survival in both primary (P = 0.002) and validation (P = 0.001) cohorts. The multivariate analysis also confirmed that high MICB expression was a significantly independent protective factor for overall survival in both primary (hazard ratio HR = 0.741, 95% CI 0.594–0.924) and validation (HR = 0.699, 95% CI 0.508–0.961) cohorts. CONCLUSION: For stage I–IV CRC patients, MICB was confirmed a novel independent prognostic factor. It could help better stratification of CRC prognosis. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1007/s00432-020-03159-0) contains supplementary material, which is available to authorized users. Springer Berlin Heidelberg 2020-04-18 2020 /pmc/articles/PMC7230058/ /pubmed/32306128 http://dx.doi.org/10.1007/s00432-020-03159-0 Text en © The Author(s) 2020 Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.
spellingShingle Original Article – Cancer Research
Feng, Qingyang
Yu, Shanchao
Mao, Yihao
Ji, Meiling
Wei, Ye
He, Guodong
Chang, Wenju
Zhu, Dexiang
Ren, Li
Xu, Jianmin
High MICB expression as a biomarker for good prognosis of colorectal cancer
title High MICB expression as a biomarker for good prognosis of colorectal cancer
title_full High MICB expression as a biomarker for good prognosis of colorectal cancer
title_fullStr High MICB expression as a biomarker for good prognosis of colorectal cancer
title_full_unstemmed High MICB expression as a biomarker for good prognosis of colorectal cancer
title_short High MICB expression as a biomarker for good prognosis of colorectal cancer
title_sort high micb expression as a biomarker for good prognosis of colorectal cancer
topic Original Article – Cancer Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7230058/
https://www.ncbi.nlm.nih.gov/pubmed/32306128
http://dx.doi.org/10.1007/s00432-020-03159-0
work_keys_str_mv AT fengqingyang highmicbexpressionasabiomarkerforgoodprognosisofcolorectalcancer
AT yushanchao highmicbexpressionasabiomarkerforgoodprognosisofcolorectalcancer
AT maoyihao highmicbexpressionasabiomarkerforgoodprognosisofcolorectalcancer
AT jimeiling highmicbexpressionasabiomarkerforgoodprognosisofcolorectalcancer
AT weiye highmicbexpressionasabiomarkerforgoodprognosisofcolorectalcancer
AT heguodong highmicbexpressionasabiomarkerforgoodprognosisofcolorectalcancer
AT changwenju highmicbexpressionasabiomarkerforgoodprognosisofcolorectalcancer
AT zhudexiang highmicbexpressionasabiomarkerforgoodprognosisofcolorectalcancer
AT renli highmicbexpressionasabiomarkerforgoodprognosisofcolorectalcancer
AT xujianmin highmicbexpressionasabiomarkerforgoodprognosisofcolorectalcancer